WoundReference improves clinical decisions
 Choose the role that best describes you
Kumar RJ, Kimble RM, Boots R, Pegg SP, et al.
ANZ journal of surgery. Date of publication 2004 Aug 1;volume 74(8):622-6.
1. ANZ J Surg. 2004 Aug;74(8):622-6. Treatment of partial-thickness burns: a prospective, randomized trial using Transcyte. Kumar RJ(1), Kimble RM, Boots R, Pegg SP. Author information: (1)Stuart Pegg Burns Unit, Royal Children's Hospital, Brisbane, Queensland, Australia. rohitjkumar@bigpond.com BACKGROUND: The purpose of the present study was to compare the effectiveness of three burns dressings (TransCyte, a bio-engineered skin substitute; Biobrane; and Silvazine cream (silver sulphadiazine and 0.2% chlorhexidine)), in treating children with partial-thickness burns. The primary objective was to determine the days until > or =90% re-epithelialization. The secondary objectives were to evaluate the number of wounds requiring autografting and the number of dressing changes/local wound care required. METHODS: Study wounds were identified on each patient and the patients were randomized to receive TransCyte or Biobrane or Silvazine. Assessment of study wound closure began at 2 days after treatment and continued at least every other day thereafter until the wounds re-epithelialized or were autografted. A laser Doppler imaging system was used as an adjunct to assessing the depth of the burn. RESULTS: Thirty-three patients with 58 wound sites enrolled in the study (TransCyte, n = 20, Biobrane, n = 17; Silvazine, n = 21). Mean time to re-epithelialization was 7.5 days for TransCyte, 9.5 days for Biobrane, and 11.2 days for Silvazine. The number of wounds requiring autografting were 5/21 (24%) for Silvazine, 3/17 (17%) for Biobrane, and 1/20 (5%) for TransCyte. CONCLUSIONS: When used in partial-thickness burns in children, TransCyte promotes fastest re-epithelialization and required less overall dressings then Biobrane or Silvazine. Patients who received Silvazine or Biobrane require more autografting than those treated with TransCyte. DOI: 10.1111/j.1445-1433.2004.03106.x PMID: 15315558 [Indexed for MEDLINE]
Appears in following Topics:
Cellular and/or Tissue Based Products